215 related articles for article (PubMed ID: 7334406)
1. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
[TBL] [Abstract][Full Text] [Related]
2. Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
Martinez-Campos A; Giovannini P; Novelli A; Cocchi D; Caraceni T; Müller EE
Acta Endocrinol (Copenh); 1982 Mar; 99(3):344-51. PubMed ID: 6803485
[TBL] [Abstract][Full Text] [Related]
3. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Rinne UK; Rinne JO
Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
Pakkenberg H; Birket-Smith E; Dupont E; Hansen E; Mikkelsen B; Presthus J; Rautakorpi I; Riman E; Rinne UK
Acta Neurol Scand; 1976 May; 53(5):376-85. PubMed ID: 1266576
[TBL] [Abstract][Full Text] [Related]
5. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
7. Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
Jensen NO; Dupont E; Hansen E; Mikkelsen B; Mikkelsen BO
Eur Neurol; 1987; 27 Suppl 1():68-72. PubMed ID: 3428310
[TBL] [Abstract][Full Text] [Related]
8. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
[TBL] [Abstract][Full Text] [Related]
9. A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease.
Chouza C; Caamaño JL; de Medina O; Aljanati R; Scaramelli A; Romero S
J Neural Transm Suppl; 1988; 27():61-70. PubMed ID: 3042913
[TBL] [Abstract][Full Text] [Related]
10. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
[TBL] [Abstract][Full Text] [Related]
11. Madopar versus sinemet. A clinical study on their effectiveness.
Korten JJ; Keyser A; Joosten EM; Gabreëls FJ
Eur Neurol; 1975; 13(2):65-71. PubMed ID: 1095374
[TBL] [Abstract][Full Text] [Related]
12. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
Grahnén A; Eckernäs SA; Collin C; Ling-Andersson A; Tiger G; Nilsson M
Eur Neurol; 1992; 32(6):343-8. PubMed ID: 1490503
[TBL] [Abstract][Full Text] [Related]
13. Enantiomeric composition of urinary salsolinol in parkinsonian patients after Madopar.
Dostert P; Strolin Benedetti M; Dordain G; Vernay D
J Neural Transm Park Dis Dement Sect; 1989; 1(4):269-78. PubMed ID: 2597313
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
Kamenetskiĭ VK
Klin Med (Mosk); 1984 Apr; 62(4):112-6. PubMed ID: 6737958
[No Abstract] [Full Text] [Related]
15. Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
Jansen EN; Meerwaldt JD; Heersema T; van Manen J; Speelman JD
Eur Neurol; 1987; 27 Suppl 1():88-92. PubMed ID: 3322841
[TBL] [Abstract][Full Text] [Related]
16. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
Birkmayer W; Birkmayer GD
J Neural Transm Suppl; 1986; 22():219-25. PubMed ID: 3097256
[TBL] [Abstract][Full Text] [Related]
17. Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response.
Agnoli A; Baldassarre M; Ruggieri S; Falaschi P; Urso RD; Rocco A
J Neural Transm; 1981; 51(1-2):123-34. PubMed ID: 7264625
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic strategies and tactics in parkinsonism].
Birkmayer W
Wien Med Wochenschr; 1986 Aug; 136(15-16):408-11. PubMed ID: 3097964
[TBL] [Abstract][Full Text] [Related]
19. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
Adv Neurol; 1987; 45():493-6. PubMed ID: 3548262
[No Abstract] [Full Text] [Related]
20. Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
Caraceni TA; Celano I; Parati E; Girotti F
J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1142-6. PubMed ID: 591982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
